

# EXPENSIVE BLOOPERS IN BUY-SELL AGREEMENTS

Save yourself some big headaches by learning from the mistakes of physicians who assumed they had everything locked up tight.

By David J. Schiller, J.D.

**O**n the surface, a buy-sell agreement between doctors joining together in practice is just a handshake on paper. But surface appearances can be deceiving. I've seen buy-sell agreements that eventually caused bitter disputes and financial hardships for both the doctor

leaving the practice and the doctors staying behind.

"That couldn't happen in *my* practice," you're probably saying. "My colleagues would never do anything to harm me." And provided no crisis arises, you're probably right. But ask yourself this: Would your buy-sell agreement be a source of problems if you or a partner became disabled? Or if the practice's income changed drastically? Or if the size of the practice were altered?

As multi-doctor practices mushroom, so do problems with buy-sell agreements—or, in unincorporated practices, problems with partner-


ship agreements. The following cases illustrate some common problems I've encountered. Could you encounter these problems? Let's hope not, but you can make sure you won't by checking now.

## Is your buyout based on current salary?

Three doctors in Pennsylvania had a thriving surgical practice. Their buy-sell agreement specified that if one of them left the practice, he'd be entitled to a year's salary, based on his most recent W-2.

Four years after the agreement was drawn up, the senior doctor gave up surgery and restricted his practice to office visits, causing his share of practice income to drop from more than \$100,000 to \$35,000. A year later, he retired. Since his buyout was based on his most recent year's salary, the doctor was entitled to only \$35,000. Had he retired outright the year before—instead of cutting back—he would have received more than \$100,000.

The remaining doctors admit-



THE AUTHOR is with the Health Care Group in Bala-Cynwyd, Pa.



**If your practice has owned its office building for several years, chances are it's a gold mine of appreciation. But allowing a departing physician to remain a landlord can have disastrous effects.**

ted that their senior partner was snagged by his own buy-sell agreement. But they too were in a financial bind. Just before the senior doctor's retirement, one of the other two had suffered a heart attack and gone on disability. The practice's income shrank by two-thirds. Not surprisingly, the remaining partner refused to pay out more than the \$35,000 the buy-sell agreement required. The senior doctor had no recourse.

To prevent this type of problem, make sure your agreement allows a doctor to negotiate his payout *before* he limits his hours or cuts back his duties. That way, he won't be penalized for slowing down instead of retiring. If the doctors can't agree on what the payout should be in case of a cut-back, the doctor who wants to curtail his practice might consider leaving the practice outright, collecting his payout, and then offering his services to the practice on an hourly basis.

#### **Are you setting yourself up for a double payout?**

One of the senior doctors in a five-doctor anesthesiology group suffered a heart attack and remained

on disability for 10 months. The practice paid his full salary for the first six months and disability insurance paid half his salary after that.

He returned to practice, but found he couldn't keep up and retired a month later. According to the terms of the buy-sell agreement, he was entitled to half a year's salary if he left the practice. Yet this meant the doctor would receive a double payout—once for salary payments during disability and once for retirement. That's because the agreement didn't require offsetting disability pay against retirement pay. So the remaining partners were forced to pay twice as much to the disabled doctor who then retired as they would have paid to a doctor who died or simply left the practice.

The doctors' buy-sell agreement needed a paragraph that would limit the payout under certain circumstances. For instance, a clause might state that after a period of disability, a doctor must spend at least as much time back in the practice as he spent disabled to collect a full retirement payout. Otherwise, his payout

would be reduced by the amount he collected while disabled.

#### **Is your buy-and-sell payout too rapid?**

An OBG specialist in New Jersey took on a junior partner two years ago. The senior doctor was well-established in the community and consequently earned two-thirds of the practice's income.

Then he became disabled and retired from the practice. The income of the practice plummeted from \$500,000 to \$170,000. But according to the buy-sell agreement, the junior doctor had to come up with \$100,000 over the next three years to buy the senior man out. The younger doctor might have been able to renegotiate the payout except for one problem: The senior doctor died soon after retirement. So instead of working out a friendly arrangement with his partner, the younger doctor ended up in a bitter dispute with his colleague's heirs.

This situation could have been prevented if the doctors had included in their buy-sell agreement a provision that limited the payout to a percentage of the practice gross each year—say, 10 per-

cent. By limiting the annual payout to a percentage of gross instead of a flat figure, the remaining doctor could have met the payout without causing strained relations or legal battles.

#### **Will a departing physician still own your real estate?**

If your practice has owned its office building for a few years, chances are it has a gold mine of appreciation locked inside. And a departing physician may be reluctant to sell out his share of that asset for a couple of reasons: First, because he'll have to pay taxes on the sale, and second, because if he retains some ownership, he or his heirs can receive income from it in the form of rent.

But allowing a departing physician to remain a landlord can have disastrous effects. A seven-doctor incorporated family practice in Connecticut learned this the hard way. The seven doctors owned equal shares in an office building that had quadrupled in value since they bought it. Over a four-year period, two of the seven doctors retired, one became disabled, and one died. Three new doctors joined the practice to replace the departing members. But the original seven families still owned the building.

As long as all the doctors shared the practice's income and ownership of the building, any rent the doctors charged the corporation came back to them as income. Now, however, not all the rent the corporation paid flowed back to the doctors in the practice. Worse

yet, when the corporation's five-year lease came up for renewal, the retired doctors or their heirs—who now had a majority interest in the building—jacked up the rent 30 percent. The practicing doctors wanted to expand the building's office space by knocking down some walls. The other owners refused; what was good for the practice was no longer in their best interest.

In this case, the majority of the building's owners no longer worked in the practice, yet they pulled the strings. But what if the opposite had been true? If just one doctor had left, it's likely the other doctors would have voted to keep rents low, and the departing physician would have suffered a loss of income by holding on to his share of the real estate.

That's why it's important to tie ownership of the practice's real estate to the ownership of the practice. To do this, your buy-sell agreement should require that a departing physician sell his share of real estate to the other doctors at current fair market value, and that the other doctors or the corporation buy it. The remaining doctors should have no trouble securing a mortgage to buy out their partner. If there's disagreement over what the fair market value of the property is, each side can choose an appraiser who will in turn agree on a third appraiser, and the three can determine a fair price for the property.

The departing physician may also choose to be the mortgage lender. By arranging an install-

**Capsules  
Ointment  
IV  
Unit Dose**

**NITRO-BID**  
(nitroglycerin)



ment sale, he'll collect interest on what's still owed him and spread his tax liability over several years. But if you're the departing physician and plan to go this route, make sure you keep your name on the property deeds until the mortgage is paid up. Otherwise, if your partner or partners die, you may have to go through the rigors of probate to collect your share of the real estate.

**Does your agreement contain a restrictive covenant?**

Besides accounts receivable and hard assets, much of the worth of

a practice is good will. When a physician leaves to set up a competing practice, he takes a chunk of the practice's goodwill value with him, so he shouldn't be entitled to a goodwill payout.

However, some buy-sell agreements ignore this issue. Take the case of a three-doctor pulmonary group in Pennsylvania. One of the doctors became dissatisfied with the practice and set up his own practice in the same office building. But because the doctors' buy-sell agreement had no provision to halt a payout in this situation, the two remaining doctors were forced



Capsules  
Ointment  
IV  
Unit Dose

**NITRO-BID**  
(nitroglycerin)



# Micronase® An advance in diabetes management

## Dosage Guide\*

Although relatively rare, hypoglycemia may occur during the conversion to MICRONASE from other therapy.

Prior therapy or condition	Considerations before starting therapy	Initial MICRONASE dose (mg/day)
Dietary therapy ineffective	No priming necessary	1.25 to 5.0 mg
Oral therapy	Discontinue oral hypoglycemic*	2.5 to 5.0 mg
Insulin therapy (< 40 units/day)	Completely discontinue insulin injections under medical supervision	2.5 to 5.0 mg
Insulin therapy (> 40 units/day)	Gradually discontinue insulin injections under close medical observation or hospitalization	5.0 mg

\*See complete prescribing information.

\*See package insert for special precautions when transferring patients from chlorpropamide.

## Micronase Tablets (brand of glyburide tablets)

**INDICATIONS AND USAGE** MICRONASE Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

**CONTRAINDICATIONS** MICRONASE Tablets are contraindicated in patients with: 1. Known hypersensitivity or allergy to the drug. 2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. 3. Type I diabetes mellitus, as sole therapy.

**SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY.** The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes, 19 (Suppl 2):747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

**PRECAUTIONS** General Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose lowering drug is used.

**Loss of Control of Blood Glucose:** In diabetic patients exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur. It may then be necessary to discontinue MICRONASE and administer insulin. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure.

**Information for Patients:** Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained. **Laboratory Tests** Response to MICRONASE Tablets should be monitored by frequent urine glucose tests and periodic blood glucose tests. Measurement of glycosylated hemoglobin levels may be helpful in some patients. **Drug Interactions** The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. **Carcinogenesis, Mutagenesis, and Impairment of Fertility** Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects. Glyburide is nonmutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay.

**Pregnancy Teratogenic Effects:** Pregnancy Category B. Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus due to glyburide. There are no adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Insulin should be used during pregnancy to maintain blood glucose as close to normal as possible. **Nonteratogenic Effects:** Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. MICRONASE should be discontinued at least two weeks before the expected delivery date. **Nursing Mothers** Some sulfonylurea drugs are known to be excreted in human milk. Insulin therapy should be considered. **Pediatric Use** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS** Hypoglycemia: See Precautions and Overdosage sections. **Gastrointestinal Reactions:** Cholestatic jaundice may occur rarely; MICRONASE Tablets should be discontinued if this occurs. Gastrointestinal disturbances, e.g., nausea, epigastric fullness, and heartburn are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose related and may disappear when dosage is reduced. **Dermatologic Reactions:** Allergic skin reactions, e.g., pruritis, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5% of treated patients during clinical trials. These may be transient and may disappear despite continued use of MICRONASE; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas. **Hematologic Reactions:** Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas. **Metabolic Reactions:** Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with MICRONASE and disulfiram-like reactions have been reported very rarely.

**OVERDOSAGE** Overdosage of sulfonylureas, including MICRONASE Tablets, can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate which will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.

**DOSAGE AND ADMINISTRATION** There is no fixed dosage regimen for the management of diabetes mellitus with MICRONASE Tablets. **Usual Starting Dose** The usual starting dose is 2.5 to 5.0 mg daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 1.25 mg daily. (See Precautions Section for patients at increased risk.) **Maximum Dose** Daily doses of more than 20 mg are not recommended. **Dosage Interval** Once-a-day therapy is usually satisfactory. Some patients, particularly those receiving more than 10 mg daily, may have a more satisfactory response with twice-a-day dosage.

**Caution:** Federal law prohibits dispensing without prescription. For additional product information see your Upjohn representative.

**Upjohn**

to pay their former partner a year's salary while he competed with them in their own office building.

In states where restrictive covenants are legal, a well-drawn one can avert such a situation. You need a provision in your buy-sell agreement that says, "If you leave the practice and set up a competing practice within *x* miles and *y* years, you'll get your share of current accounts receivable and hard assets, but nothing for good will." Ideally, this will make your restive partner think twice about setting up shop just down the street, but isn't so restrictive as to raise dark thoughts in a judge's mind about being anti-competitive and contrary to the public interest. However, if your partner leaves, collects his goodwill payout, and then returns to your area before the restrictive covenant expires, you'll have to sue to get the money back.

## Must you show cause to get rid of a difficult partner?

I'd be willing to bet that 75 percent of the buy-sell agreements out there have a paragraph that lists the causes for which a partner can be expelled from the practice. These causes are usually extreme: loss of medical license, a felony conviction, mental incompetence.

It would seem fair not to terminate a partner except under extreme circumstances. But I've seen entire practices go down the tubes because of one partner's constant irritability. Not long



ago, three young surgeons from New Jersey complained to me that their fourth partner, a 55-year-old doctor, had become increasingly difficult to get along with. He yelled at patients and nurses, disrupted staff meetings, demanded that his call schedule be reduced, and refused to agree to any changes the other doctors wanted. Things were so bad that patients and referring doctors had started turning away from the practice.

The doctors would have liked to oust him from the practice by majority vote. But their buy-sell agreement listed the conditions under which he could be terminated, and "general irritability" wasn't one of them. They finally did get the fourth partner to leave—but they had to pay a heavy premium in addition to his payout to get him to agree.

That's why I recommend that buy-sell agreements state that any partner can be removed from the practice for any reason by ma-

jority vote. As harsh as that may sound, the practice should come first. The partner forced out should be entitled to the same payout as a doctor who leaves voluntarily, but you won't have to bribe him to leave.

If your buy-sell agreement doesn't contain these provisions, what should you do? First, talk to your partners. Most of these provisions are as beneficial to a doctor leaving a practice as to the ones staying, so you should be able to reach an agreement quickly. Once you all agree, notify your attorney that you'd like to add to your buy-sell agreement. You probably don't need to have a new document drafted. Just add the clauses to the old one.

Keep in mind too that a buy-sell agreement need not be engraved in stone. If the practice changes or you and your partners decide you want to revise the agreement, you can. Just don't wait until a crisis hits. Otherwise, you could end up like these physicians. ■

### Scared away

As I discussed a patient's case in my consultation room, I wasn't aware that the 4-year-old grandson she'd brought along was looking around wide-eyed. I later learned that he'd paid particular notice to the 18-inch, built-to-scale skeleton that reposes on my desk. When they left the office, the boy told his grandmother that he'd never want to go to that doctor. When she asked why, he said: "Didn't you see what he does to little kids?"

—Howard J. Ickes, M.D.

## WANT TO SELL

- ☐ EQUIPMENT?
- ☐ A VACATION HOME?
- ☐ A PRACTICE?
- ☐ OR FILL A POSITION?

Let us fill your need with

## MEDICAL ECONOMICS CLASSIFIED.

You can sell almost anything physicians need and want, as many of your colleagues do, by using the Medical Economics Classified section. Such notices produce results because they're in the best-read journal for doctors.

Physicians everywhere scan the notices for information about practices, positions, placement opportunities, and office equipment. They also look for investment advice, vacation rentals, resorts, art for sale, and more. It's the only advertising listed on our contents page.

### It's easy to participate

Just send us your classified notice. Each line costs only \$19 with a minimum of \$95 per ad. (For multiple insertions—\$17/line, min. \$85). Use 52 characters as an average count per line. Classified ads in display type are also available. For more information contact:

Classified Advertising

**medical  
economics**

680 Kinderkamack Rd.  
Oradell, N.J. 07649  
(201) 262-3030